These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11571741)

  • 21. Multimodal treatment of children with unresectable or recurrent desmoid tumors: an 11-year longitudinal observational study.
    Lackner H; Urban C; Benesch M; Raith J; Moser A; Sovinz P; Schwinger W; Dornbusch HJ; Triebl-Roth K
    J Pediatr Hematol Oncol; 2004 Aug; 26(8):518-22. PubMed ID: 15284591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibromatosis of the neck causing airway obstruction managed effectively with weekly low-dose methotrexate and vinblastine.
    Sze H; Yeung MW
    Hong Kong Med J; 2009 Jun; 15(3):221-3. PubMed ID: 19494380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
    Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
    Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
    Sparber-Sauer M; Seitz G; von Kalle T; Vokuhl C; Leuschner I; Scheer M; Münter M; Ljungman G; Bielack SS; Niggli F; Ladenstein R; Klingebiel T; Fuchs J; Koscielniak E;
    Pediatr Blood Cancer; 2018 May; 65(5):e26943. PubMed ID: 29316163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful combined treatment for giant mesenteric desmoid tumor: case report and review of the literature.
    Federici S; Mordenti M; Domenichelli V; Pelusi G; Straziuso S; Pericoli R
    J Pediatr Surg; 2012 Jun; 47(6):e25-30. PubMed ID: 22703821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
    Ravaioli A; Nicoletti S; Tamburini E; Papi M
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India.
    Bajpai J; Munot P; Kota K; Gupta G; Gala K; Gulia A; Rekhi B; Khanna N; Shetty N; Bhargava P; Srinivas S; Ostwal V; Patil V; Noronha V; Kulkarni S; Laskar S; Prabhash K; Chinnaswamy G; Gupta S; Banavali S
    JCO Glob Oncol; 2024 May; 10():e2300308. PubMed ID: 38723218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; Bianco V; Francini E
    Anticancer Drugs; 2015 Sep; 26(8):878-83. PubMed ID: 26053279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
    Wagenaar HC; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave AJ; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla JP; Nooij MA; Poveda A; Scotto di Palumbo V; Vermorken JB
    Gynecol Oncol; 2001 Jun; 81(3):348-54. PubMed ID: 11371121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
    Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S
    Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.
    Boccardo F; Pace M; Guarneri D; Canobbio L; Curotto A; Martorana G
    Cancer; 1994 Apr; 73(7):1932-6. PubMed ID: 8137220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
    Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
    J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
    Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.